Price comparison of various versions of Elotuzumab injection

Elotuzumab (Elotuzumab) is an immunomodulatory monoclonal antibody targeting SLAMF7 and is widely used to treat multiple myeloma (MM). In the domestic market, evolizumab has not yet received marketing approval, so its price and medical insurance policy have not yet been clarified. Overseas, evolizumab has been launched in many countries, especially in the European and American markets, where it is widely used in the treatment of multiple myeloma. The price of the European version of the original drug varies depending on the region and exchange rate fluctuations. Generally speaking, a box of 300 mg evolizumab is priced at approximately RMB 15,000. The price may fluctuate due to exchange rate changes and different policies of various countries.

Currently, there are no generic drugs of evolizumab available for sale overseas, which means that patients can only choose to purchase the original drug. Original drugs are usually priced higher and are unlikely to see significant price cuts. This is because monoclonal antibody drugs usually have longer patent protection periods, higher research and development costs, and longer production cycles. Since the drug has not yet entered the generic market, patients need to consider cost when making their choice. In addition, the price of evolizumab is also affected by local medical insurance policies. For example, in the United States, evolizumab is relatively expensive and may be reimbursed to a certain extent through medical insurance. In other countries, governments may reach price agreements with pharmaceutical companies to make drugs less affordable.

However, as evolizumab becomes more widely available, price competition may arise. The launch of generic drugs can drive down prices, especially in some large markets, where the launch of generic drugs often affects drug pricing. Although there are currently no generic drugs, with the opening of the market and changes in drug policies, more products with competitive prices may enter the market in the future, further reducing the burden on patients.

Reference materials:https://www.empliciti.com/